alpha-Bisabolol oxide A is one of the hallmark oxygenated sesquiterpenes in German chamomile essential oil. The strongest public evidence supports its identity, repeated occurrence in chamomile chemotypes, and a limited early-stage literature that includes antioxidant assays and a recent prostate-cell nanoparticle study. Compared with alpha-bisabolol itself, the standalone evidence base for bisabolol oxide A is thinner, so AromaForge should describe it primarily as a chamomile marker constituent with exploratory laboratory bioactivity rather than established medical use.
Chemical identity and composition
NIST and PubChem identify alpha-bisabolol oxide A as C15H26O2 with CAS 22567-36-8. Open chamomile chemistry papers consistently place it among the dominant bisabolane-type oxygenated sesquiterpenes. In the Estonia chamomile paper it accounted for 20-33% of the oil, while a 2025 Bulgarian study reported 6.1-7.3% in beta-farnesene-rich German chamomile oils from two producers, underscoring chemotype and producer variation.
Aroma and practical use
- Use the recorded soft, herbal, woody, chamomile-like, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The Estonia chamomile composition paper identified bisabolol oxide A as the dominant constituent in the sampled oils at 20-33% of total GC peak area.
That paper is strong identity and occurrence evidence for oxide-rich German chamomile chemotypes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2018 comparative assay reported stronger DPPH radical-scavenging activity for alpha-bisabolol oxide A than for alpha-bisabolol and the tested chamomile oil.
The paper reports an IC50 of 1.50 mg/mL for oxide A versus 43.88 mg/mL for alpha-bisabolol and 2.20 mg/mL for the whole oil in the same assay system.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025/2026 abstracted DU-145 study reported that bisabolol oxide A-loaded nanoparticles inhibited proliferation, reduced migratory capacity, and shifted apoptosis-related molecular readouts.
The indexed abstract describes time-dependent IC50 values, lower migration, and changes involving miR-34a, miR-181a, CTNNB, SMAD3, EGFR, P53, and CASP9.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Screening assumption (family fallback). It is not a verified constituent-specific exposure limit.
model fallback · Tisserand Institute — sesquiterpene alcohols/oxides generally regarded as low sensitization riskNo constituent-specific public cosmetic safety monograph comparable to broad chamomile or alpha-bisabolol reviews was located for isolated bisabolol oxide A.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because direct benefit literature is sparse and partly formulation-specific, copy should avoid presenting bisabolol oxide A as a proven standalone therapeutic agent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
free-radical scavenging in DPPH assay
In a comparative chamomile-component assay, alpha-bisabolol oxide A showed measurable DPPH radical-scavenging activity and a lower IC50 than alpha-bisabolol in that specific setup.
This experimental finding does not establish benefit, dose or safety in people using this blend.
cell-model apoptosis and migration signaling changes
The DU-145 nanoparticle study reported altered apoptosis- and migration-related readouts together with docking results involving beta-catenin and EGFR, but this is still preliminary laboratory evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a dedicated human clinical study on isolated bisabolol oxide A.
- Part of the accessible activity literature uses nanoparticle formulations rather than unformulated oxide A, which lowers direct translation confidence.
- Direct constituent-specific dermal, sensitization, and phototoxicity data for isolated bisabolol oxide A were not located in the reviewed public sources.
- No IFRA Standard, Tisserand monograph, or RIFM safety assessment specific to isolated alpha-Bisabolol oxide A (CAS 22567-36-8) was located; the IFRA Standard for alpha-Bisabolol (CAS 515-69-5, Amendment 49) applies to a structurally distinct parent alcohol, not this oxide, and is not used here as a constituent-specific limit.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.